[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525189":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":34,"centralContacts":43,"locations":53,"responsibleParty":71,"collaborators":75,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":87,"minAge":88,"maxAge":34,"enrollmentInfo":89,"targetDuration":34,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":34,"overallStatus":55,"whyStopped":34,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Medical University of South Carolina","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Adaptive Randomization 1","EXPERIMENTAL","This arm includes people who did not respond to 4 weeks of pharmacotherapy (either varenicline or combination NRT). After a 4-week course of pharmacotherapy, participants that are not responding to medication will receive four weeks of the other FDA approved option, either varenicline or combination NRT, with instructions to try to quit again",[13],"Behavioral: Switching to a different medication",{"label":15,"type":10,"description":16,"interventionNames":17},"Non-Adaptive Randomization 1","This arm includes people who did not respond to 4 weeks of pharmacotherapy (either varenicline or combination NRT). After a 4-week course of pharmacotherapy, participants that are not responding to the medication will receive four additional weeks of the same medication with instructions to try to quit again",[18],"Behavioral: Continued use of the same medication",{"label":20,"type":10,"description":21,"interventionNames":22},"Harm Reduction Randomization 2","This arm includes people who did not respond to two 4-week courses of pharmacotherapy (either varenicline or combination NRT or both). After two 4-week courses of pharmacotherapy, participants who are not responding to medication will be randomly assigned to a harm reduction group (e-cigarettes). Participants assigned to the harm reduction group will receive four weeks of e-cigarette product with instructions to switch completely",[23],"Behavioral: Switching to a harm reduction tobacco product",{"label":25,"type":10,"description":26,"interventionNames":27},"Non-Adaptive Randomization 2","This arm includes people who did not respond to two 4-week courses of pharmacotherapy (either varenicline or combination NRT or both sequentially). After two four-week courses of pharmacotherapy, participants that are not responding to the medication will receive four additional weeks of the same medication with instructions to try to quit again.",[18],[29,35,39],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"BEHAVIORAL","Switching to a different medication","Participants will receive four weeks of the other FDA approved option, either varenicline or combination NRT, with instructions to try to quit again at week 4.",[9],null,{"type":30,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"Continued use of the same medication","Participants will receive four additional weeks of the same medication (varenicline or NRT) with instructions to try to quit again at week 4.",[15,25],{"type":30,"name":40,"description":41,"armGroupLabels":42,"otherNames":34},"Switching to a harm reduction tobacco product","Participants will receive four weeks of e-cigarette products with instructions to switch completely at Week 8",[20],[44,49],{"name":45,"role":46,"phone":47,"phoneExt":34,"email":48},"Tracy T Smith, PhD","CONTACT","8438725164","smithtra@musc.edu",{"name":50,"role":46,"phone":51,"phoneExt":34,"email":52},"Matthew J Carpenter, PhD","8438762436","carpente@musc.edu",[54],{"facility":5,"status":55,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"RECRUITING","Charleston","South Carolina","29425","United States","US",{"type":62,"coordinates":63},"Point",[64,65],-79.93275,32.77632,{"lat":65,"lon":64},[68],{"name":69,"role":46,"phone":34,"phoneExt":34,"email":70},"William McCamy","mccamy@musc.edu",{"type":72,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"PRINCIPAL_INVESTIGATOR","Tracy Smith","Associate Professor",[76],{"name":77,"class":78},"National Cancer Institute (NCI)","NIH","100525189","a-clinical-trial-of-adaptive-treatment-for-early-smoking-cessation-relapse-100525189",false,"NCT06118502","A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse","ADAPT","Inclusion Criteria:\n\n* Smokers who want to quit\n\nExclusion Criteria:\n\n* Non-smokers",true,"ALL","21 Years",{"count":90,"type":91},544,"ESTIMATED","INTERVENTIONAL",[94],"NA","This is a research study to find out if treatment decision making can be improved for smokers who find it difficult to quit with medications. Everyone who participates in this study will receive free product, either nicotine replacement therapies (patches and lozenges), varenicline, or a harm reduction product (e-cigarette) for a full 12 weeks. Most participants will receive some combination of these treatments, depending on individual response to each.\n\nAll visits and study assessments will be entirely remote. All treatments will be provided free of charge for the first 12 weeks. After that, the study team will contact the participants 6 months after the first study phone call to complete another survey. The study lasts six months and will involve 8 surveys.",[97,98,99],"Cigarette Smoking","Smoking Behaviors","Treatment","2026-03-04",{"date":102,"type":103},"2026-03-06","ACTUAL",{"date":105,"type":103},"2024-03-25",{"date":107,"type":91},"2028-03-31",{"name":5,"class":6},1]